Browse MAD2L1

Summary
SymbolMAD2L1
NameMAD2 mitotic arrest deficient-like 1 (yeast)
Aliases MAD2 (mitotic arrest deficient, yeast, homolog)-like 1; MAD2-like protein 1; mitotic arrest deficient 2-like ......
Chromosomal Location4q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus. Chromosome, centromere, kinetochore. Cytoplasm. Cytoplasm, cytoskeleton, spindle pole. Note=Recruited by MAD1L1 to unattached kinetochores (Probable). Recruited to the nuclear pore complex by TPR during interphase. Recruited to kinetochores in late prometaphase after BUB1, CENPF, BUB1B and CENPE. Kinetochore association requires the presence of NEK2. Kinetochore association is repressed by UBD.
Domain PF02301 HORMA domain
Function

Component of the spindle-assembly checkpoint that prevents the onset of anaphase until all chromosomes are properly aligned at the metaphase plate. Required for the execution of the mitotic checkpoint which monitors the process of kinetochore-spindle attachment and inhibits the activity of the anaphase promoting complex by sequestering CDC20 until all chromosomes are aligned at the metaphase plate.

> Gene Ontology
 
Biological Process GO:0000070 mitotic sister chromatid segregation
GO:0000075 cell cycle checkpoint
GO:0000819 sister chromatid segregation
GO:0007059 chromosome segregation
GO:0007062 sister chromatid cohesion
GO:0007067 mitotic nuclear division
GO:0007088 regulation of mitotic nuclear division
GO:0007091 metaphase/anaphase transition of mitotic cell cycle
GO:0007093 mitotic cell cycle checkpoint
GO:0007094 mitotic spindle assembly checkpoint
GO:0007346 regulation of mitotic cell cycle
GO:0009894 regulation of catabolic process
GO:0009895 negative regulation of catabolic process
GO:0009896 positive regulation of catabolic process
GO:0010498 proteasomal protein catabolic process
GO:0010639 negative regulation of organelle organization
GO:0010948 negative regulation of cell cycle process
GO:0010965 regulation of mitotic sister chromatid separation
GO:0030071 regulation of mitotic metaphase/anaphase transition
GO:0031145 anaphase-promoting complex-dependent catabolic process
GO:0031329 regulation of cellular catabolic process
GO:0031331 positive regulation of cellular catabolic process
GO:0031396 regulation of protein ubiquitination
GO:0031397 negative regulation of protein ubiquitination
GO:0031398 positive regulation of protein ubiquitination
GO:0031577 spindle checkpoint
GO:0033044 regulation of chromosome organization
GO:0033045 regulation of sister chromatid segregation
GO:0033046 negative regulation of sister chromatid segregation
GO:0033047 regulation of mitotic sister chromatid segregation
GO:0033048 negative regulation of mitotic sister chromatid segregation
GO:0042176 regulation of protein catabolic process
GO:0042177 negative regulation of protein catabolic process
GO:0042787 protein ubiquitination involved in ubiquitin-dependent protein catabolic process
GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044784 metaphase/anaphase transition of cell cycle
GO:0045732 positive regulation of protein catabolic process
GO:0045786 negative regulation of cell cycle
GO:0045787 positive regulation of cell cycle
GO:0045839 negative regulation of mitotic nuclear division
GO:0045841 negative regulation of mitotic metaphase/anaphase transition
GO:0045862 positive regulation of proteolysis
GO:0045930 negative regulation of mitotic cell cycle
GO:0045931 positive regulation of mitotic cell cycle
GO:0051304 chromosome separation
GO:0051306 mitotic sister chromatid separation
GO:0051348 negative regulation of transferase activity
GO:0051436 negative regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle
GO:0051437 positive regulation of ubiquitin-protein ligase activity involved in regulation of mitotic cell cycle transition
GO:0051438 regulation of ubiquitin-protein transferase activity
GO:0051439 regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle
GO:0051443 positive regulation of ubiquitin-protein transferase activity
GO:0051444 negative regulation of ubiquitin-protein transferase activity
GO:0051783 regulation of nuclear division
GO:0051784 negative regulation of nuclear division
GO:0051983 regulation of chromosome segregation
GO:0051985 negative regulation of chromosome segregation
GO:0071173 spindle assembly checkpoint
GO:0071174 mitotic spindle checkpoint
GO:0090068 positive regulation of cell cycle process
GO:0090231 regulation of spindle checkpoint
GO:0090232 positive regulation of spindle checkpoint
GO:0090266 regulation of mitotic cell cycle spindle assembly checkpoint
GO:0090267 positive regulation of mitotic cell cycle spindle assembly checkpoint
GO:0098813 nuclear chromosome segregation
GO:1901976 regulation of cell cycle checkpoint
GO:1901978 positive regulation of cell cycle checkpoint
GO:1901987 regulation of cell cycle phase transition
GO:1901988 negative regulation of cell cycle phase transition
GO:1901990 regulation of mitotic cell cycle phase transition
GO:1901991 negative regulation of mitotic cell cycle phase transition
GO:1902099 regulation of metaphase/anaphase transition of cell cycle
GO:1902100 negative regulation of metaphase/anaphase transition of cell cycle
GO:1903050 regulation of proteolysis involved in cellular protein catabolic process
GO:1903052 positive regulation of proteolysis involved in cellular protein catabolic process
GO:1903320 regulation of protein modification by small protein conjugation or removal
GO:1903321 negative regulation of protein modification by small protein conjugation or removal
GO:1903322 positive regulation of protein modification by small protein conjugation or removal
GO:1903362 regulation of cellular protein catabolic process
GO:1903364 positive regulation of cellular protein catabolic process
GO:1903504 regulation of mitotic spindle checkpoint
GO:1904666 regulation of ubiquitin protein ligase activity
GO:1904667 negative regulation of ubiquitin protein ligase activity
GO:1904668 positive regulation of ubiquitin protein ligase activity
GO:2000058 regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process
GO:2000060 positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process
GO:2000816 negative regulation of mitotic sister chromatid separation
GO:2001251 negative regulation of chromosome organization
Molecular Function -
Cellular Component GO:0000775 chromosome, centromeric region
GO:0000776 kinetochore
GO:0000777 condensed chromosome kinetochore
GO:0000779 condensed chromosome, centromeric region
GO:0000793 condensed chromosome
GO:0000922 spindle pole
GO:0005635 nuclear envelope
GO:0005643 nuclear pore
GO:0005819 spindle
GO:0072686 mitotic spindle
GO:0098687 chromosomal region
> KEGG and Reactome Pathway
 
KEGG hsa04110 Cell cycle
hsa04114 Oocyte meiosis
hsa04914 Progesterone-mediated oocyte maturation
Reactome R-HSA-179409: APC-Cdc20 mediated degradation of Nek2A
R-HSA-174143: APC/C-mediated degradation of cell cycle proteins
R-HSA-176409: APC/C
R-HSA-179419: APC
R-HSA-176814: Activation of APC/C and APC/C
R-HSA-141444: Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
R-HSA-141424: Amplification of signal from the kinetochores
R-HSA-174184: Cdc20
R-HSA-1640170: Cell Cycle
R-HSA-69620: Cell Cycle Checkpoints
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-141430: Inactivation of APC/C via direct inhibition of the APC/C complex
R-HSA-141405: Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components
R-HSA-68886: M Phase
R-HSA-68882: Mitotic Anaphase
R-HSA-2555396: Mitotic Metaphase and Anaphase
R-HSA-68877: Mitotic Prometaphase
R-HSA-69618: Mitotic Spindle Checkpoint
R-HSA-195258: RHO GTPase Effectors
R-HSA-5663220: RHO GTPases Activate Formins
R-HSA-176408: Regulation of APC/C activators between G1/S and early anaphase
R-HSA-453276: Regulation of mitotic cell cycle
R-HSA-2500257: Resolution of Sister Chromatid Cohesion
R-HSA-2467813: Separation of Sister Chromatids
R-HSA-162582: Signal Transduction
R-HSA-194315: Signaling by Rho GTPases
Summary
SymbolMAD2L1
NameMAD2 mitotic arrest deficient-like 1 (yeast)
Aliases MAD2 (mitotic arrest deficient, yeast, homolog)-like 1; MAD2-like protein 1; mitotic arrest deficient 2-like ......
Chromosomal Location4q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MAD2L1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolMAD2L1
NameMAD2 mitotic arrest deficient-like 1 (yeast)
Aliases MAD2 (mitotic arrest deficient, yeast, homolog)-like 1; MAD2-like protein 1; mitotic arrest deficient 2-like ......
Chromosomal Location4q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MAD2L1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 1.18 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolMAD2L1
NameMAD2 mitotic arrest deficient-like 1 (yeast)
Aliases MAD2 (mitotic arrest deficient, yeast, homolog)-like 1; MAD2-like protein 1; mitotic arrest deficient 2-like ......
Chromosomal Location4q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MAD2L1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0270.929
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0290.989
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0680.964
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1850.686
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.020.983
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.3830.753
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2560.529
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.5560.7
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1890.896
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.4870.664
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.6030.721
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.498.91e-05
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MAD2L1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMAD2L1
NameMAD2 mitotic arrest deficient-like 1 (yeast)
Aliases MAD2 (mitotic arrest deficient, yeast, homolog)-like 1; MAD2-like protein 1; mitotic arrest deficient 2-like ......
Chromosomal Location4q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MAD2L1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMAD2L1
NameMAD2 mitotic arrest deficient-like 1 (yeast)
Aliases MAD2 (mitotic arrest deficient, yeast, homolog)-like 1; MAD2-like protein 1; mitotic arrest deficient 2-like ......
Chromosomal Location4q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MAD2L1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MAD2L1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMAD2L1
NameMAD2 mitotic arrest deficient-like 1 (yeast)
Aliases MAD2 (mitotic arrest deficient, yeast, homolog)-like 1; MAD2-like protein 1; mitotic arrest deficient 2-like ......
Chromosomal Location4q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MAD2L1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMAD2L1
NameMAD2 mitotic arrest deficient-like 1 (yeast)
Aliases MAD2 (mitotic arrest deficient, yeast, homolog)-like 1; MAD2-like protein 1; mitotic arrest deficient 2-like ......
Chromosomal Location4q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MAD2L1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMAD2L1
NameMAD2 mitotic arrest deficient-like 1 (yeast)
Aliases MAD2 (mitotic arrest deficient, yeast, homolog)-like 1; MAD2-like protein 1; mitotic arrest deficient 2-like ......
Chromosomal Location4q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MAD2L1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMAD2L1
NameMAD2 mitotic arrest deficient-like 1 (yeast)
Aliases MAD2 (mitotic arrest deficient, yeast, homolog)-like 1; MAD2-like protein 1; mitotic arrest deficient 2-like ......
Chromosomal Location4q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MAD2L1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.